Key result
Implantation of the Tetrilimus everolimus-eluting stent in real-world patients with coronary artery disease resulted in a 1-year target lesion failure rate of 3.7%.
Why the study?
The study aimed to evaluate the 1-year safety and clinical performance of the Tetrilimus biodegradable polymer-coated ultra-thin everolimus-eluting stent in real-world patients with coronary artery disease.
Observational (n=594)
Yes
Biodegradable polymer-coated ultra-thin everolimus-eluting stents demonstrated low rates of target lesion failure and stent thrombosis at 1 year in a real-world cohort.
Registry data support Tetrilimus feasibility in CAD; leaves open comparative efficacy versus other stents in RCTs.
BACKGROUND: Tetrilimus (Sahajanand Medical Technologies Limited, Surat, India) is a biodegradable polymer-coated everolimus-eluting stent with cobalt-chromium stent platform and ultra-thin (60 µm) strut thickness. We aimed to report 1-year safety and clinical performance of Tetrilimus everolimus-eluting stent in patients with coronary artery disease in "real-world" clinical practice. METHODS: The PERFORMance of biodegradable polymer-coated ultra-thin EVERolimuseluting stents was an observational, multicenter, single-arm, and investigator-initiated retrospective registry. All "real-world" patients who had received Tetrilimus everolimuseluting stent between July-2015 and October-2016 at four study centers were analyzed. The data were collected retrospectively either by extraction from existing databases in consecutive fashion where index and follow-up data existed or the follow-up was obtained by telephonic contact. Primary endpoint was 1-year incidence of target lesion failure, which was defined as a composite endpoint of cardiac death, myocardial infarction, and target lesion revascularization by percutaneous or surgical methods. The Academic Research Consortium-defined stent thrombosis was assessed as additional safety endpoint. RESULTS: During the study period, 815 Tetrilimus everolimus-eluting stents (1.4 ± 0.5 stent/ patient) were implanted to treat 735 coronary lesions (1.1 ± 0.3 stent/lesion) in 594 patients (mean age: 55.6 ± 12.1 years). The cumulative incidence of target lesion failure at 1-year follow-up was 3.7%, which included 9 (1.5%) cardiac deaths, 8 (1.4%) myocardial infarctions, and 5 (0.8%) target lesion revascularizations. There were 5 (0.8%) cases of probable stent thrombosis and 4 (0.7%) cases of possible stent thrombosis at 1-year follow-up. CONCLUSION: Low incidences of target lesion failure and stent thrombosis at 1-year followup indicates that biodegradable polymer-coated ultra-thin Tetrilimus everolimus-eluting stents may have encouraging safety and efficacy in unselected real-world patients with coronary artery disease, including those with high-risk characteristics and complex lesions.
No takes yet. Share an insight, caveat, or question.
Kasturi et al. (2022) conducted an observational in coronary artery disease (n=594). Tetrilimus everolimus-eluting stent was evaluated on 1-year incidence of target lesion failure (composite of cardiac death, myocardial infarction, and target lesion revascularization). Implantation of the Tetrilimus everolimus-eluting stent in real-world patients with coronary artery disease resulted in a 1-year target lesion failure rate of 3.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: